| Authors: |
Schaefer DA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA., Longley RM; Icahn School of Medicine at Mount Sinai, New York, NY., Wolfe ED; University of Washington School of Public Health, Department of Health Systems and Population Health, Seattle, WA., Keane EP; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA., Larizza IS; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA., Boardman AC; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA., Rosenberg J; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA., Mate-Kole M; Beth Israel Deaconess Medical Center, Boston, MA., Waldman LP; Harvard Medical School, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Majhail N; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN., Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ., Amonoo HL; Harvard Medical School, Boston, MA; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA; Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: hermioni_amonoo@dfci.harvard.edu. |
